Access to Medicines
Health is one of our most important personal assets and medicines play an essential role in preserving it. Yet around the world, millions lack access to comprehensive healthcare, including medicines and other treatment tools. Lilly is committed to expanding access to medicines, and we work with partners to improve health outcomes for under-served populations.
We recognise that poor disease outcomes—especially among low-income populations—are about more than medicine alone. Meeting patients’ needs is the result of a complex coordination of healthcare tools, healthcare professionals, a supporting infrastructure, and appropriate measurement, evaluation, and regulatory capabilities.
In 2011, we launched a new platform to help address these issues, The Lilly Global Health Innovation Campaign. The campaign encompasses two of Lilly’s signature public/private programs, The Lilly NCD Partnership and The Lilly MDR-TB Partnership.
The Lilly Non-Communicable Disease Partnership has seen an investment of $30 million over five years to research new, comprehensive approaches to treat NCDs in the developing world, where they account for nearly 80 percent of deaths. Lilly has also invested millions in addressing Multi-Drug Resistant TB through a combination of international partnerships and technology transfer programmes.
In addition to investing in these public/private partnerships, we use multiple other strategies to help increase access to medicines, including exploring differential pricing for medicines; not enforcing intellectual property rights for Lilly medicines in least-developed countries (LDCs) as defined by the United Nations; and providing donations for PAP on Lilly products through our Lilly TruAssist program and Life for a Child.
Through our Life For a Child programme, Lilly has committed to donating more than 800,000 vials of insulin to the International Diabetes Federation's Life for a Child program between 2008 and 2013. These donations, initially focused on 12 countries in sub-Saharan Africa, have now expanded to include 21 countries throughout Africa, Asia, and South America. The medicine will help as many as 24,000 children who do not have access to diabetes treatment.
In times of disaster, we donate medicines to those in need. We also support programmes that improve patient outcomes, such as scholarships, award recognitions, and tools for healthy living.